Xspray Pharma handed CRL from US regulators seeking more information about leukemia treatment
Xspray Pharma has been given a complete response letter from the FDA over the NDA for its leukemia treatment Dasynoc, which it had expected to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
